Drug Trial Radar · NCT07564141
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
688
Planned (sponsor's estimate)
Start
Aug 28, 2026
Primary completion
Dec 2029
Study completion Nov 2031
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- May 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study will be conducted in different countries around the world with up to about 688 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with or without bevacizumab and how it compares to an investigator's choice of platinum-based chemotherapy with or without bevacizumab. Participants will receive either: * Rina-S monotherapy (by itself), * Rina-S plus bevacizumab, * investigator's choice chemotherapy (by itself) (standard of care), or * investigator's choice chemotherapy plus bevacizumab (standard of care). No participants will be given placebo. Participants will participate in 1 of 2 arms. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 or 4 weeks, depending on medication received). During visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity and imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) will be different for every participant.
Conditions
- Platinum-Sensitive Ovarian Cancer
- Ovarian Cancer
Interventions
Rina-SBiological
Intravenous (IV) infusion
BevacizumabDrug
IV infusion
CarboplatinDrug
IV infusion
GemcitabineDrug
IV infusion
PaclitaxelDrug
IV infusion
PLDDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, as Determined by Blinded Independent Central Review (BICR)Time frame: Up to approximately 3 years
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
Danbury Hospital
Danbury, Connecticut · Recruiting
Compass Oncology - West Cancer Center (Northwest Cancer Specialists, P.C.)
Tigard, Oregon · Recruiting
Alliance Cancer Specialists, PC
Bensalem, Pennsylvania · Recruiting
Utah Cancer Specialists
South Jordan, Utah · Recruiting
West Virginia University
Morgantown, West Virginia · Recruiting
ProHealth Care Inc
Waukesha, Wisconsin · Recruiting
Tampere University Hospital
Tampere, Pirkanmaa, Finland · Recruiting
The Cancer Institute Hospital of JFCR
Tokyo, Koto City, Japan · Recruiting
Niigata Cancer Center Hospital
Chuo Ku Niigata, Niigata, Japan · Recruiting
Tokushima University Hospital
Tokushima, Tokushima, Japan · Recruiting
Yamagata University Hospital
Yamagata, Yamagata, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.